Methicillin resistant Staphylococcus aureus is the organism most antibacterial programs are asked about first, and for good reason. It is common, it is well characterised, and the resistance that defines it is a single elegant trick that removes an entire drug class from play.
What makes an isolate MRSA
S. aureus builds its cell wall using penicillin binding proteins. Beta-lactams work by binding those proteins and stopping the crosslinking step. MRSA carries an extra gene, mecA (or the less common mecC), sitting on a mobile element called SCCmec. That gene encodes PBP2a, an alternative penicillin binding protein with very low affinity for beta-lactams.
The consequence is not resistance to methicillin specifically. It is resistance to essentially the whole beta-lactam class at once, because the organism has acquired a spare part that the class cannot bind. That is why a single genetic marker changes the entire treatment and screening picture, and why a compound series with a beta-lactam warhead has to answer the PBP2a question early.
The exceptions worth knowing
Two later generation cephalosporins, ceftaroline and ceftobiprole, do bind PBP2a with useful affinity, which shows the mechanism is a binding problem rather than an impenetrable wall. If your scaffold is a beta-lactam, that is the part of the literature worth reading closely before writing the series off.
What still works, and what is under pressure
- Vancomycin, the long standing reference agent. Not affected by PBP2a because it binds the D-Ala-D-Ala substrate rather than the enzyme. Reduced susceptibility does occur and matters clinically.
- Daptomycin, a lipopeptide acting on the membrane. Resistance appears through membrane charge changes rather than through mec.
- Linezolid, an oxazolidinone binding the 50S ribosomal subunit. Resistance is uncommon and usually involves ribosomal mutation or the cfr gene.
- Ceftaroline, the anti-MRSA cephalosporin noted above.
- Fluoroquinolones are generally not useful against MRSA lineages: resistance through gyrA and grlA target mutation is widespread, which is exactly what a screen against MRSA will tell you.
Why MRSA is the Gram-positive benchmark for screening
A Gram-positive organism has no outer membrane, so the uptake problem that dominates Gram-negative bacteria is largely absent. What remains is target engagement and acquired resistance. That makes MRSA a clean test of whether a compound has real antibacterial activity at all, uncomplicated by permeability.
In practice this means a series that fails on MRSA rarely gets rescued on Gram-negatives, while a series that works beautifully on MRSA still has everything to prove against E. coli. Screening both is the point of running a panel rather than a single organism.
Typical MIC ranges to calibrate against
Any predicted band is only meaningful next to what is already known. These are the ranges commonly reported for reference agents against MRSA, useful as a sanity check when you read a screen:
| Agent | Class | Usual MRSA behaviour |
|---|---|---|
| Oxacillin | Beta-lactam | Resistant by definition of the phenotype |
| Vancomycin | Glycopeptide | Low single digit µg/mL, susceptible in most isolates |
| Daptomycin | Lipopeptide | Low µg/mL, susceptible in most isolates |
| Linezolid | Oxazolidinone | Low single digit µg/mL, susceptible in most isolates |
| Ciprofloxacin | Fluoroquinolone | Frequently resistant, wide band |
Exact breakpoints are set by CLSI and EUCAST and are revised, so treat this table as orientation rather than as a breakpoint reference. The minimum inhibitory concentration guide explains how the numbers are produced and why a band, not a point value, is the honest unit.
Screening a compound against MRSA
A screen against MRSA answers three questions in one pass: does the compound have intrinsic activity on a Gram-positive organism, is the likely resistance route already present in circulating lineages, and how much published support sits behind that call. If the mechanism named is target mutation rather than efflux, the fix is a scaffold decision, not a formulation decision.
MRSA is also the organism that turns most often into a broader antibiotic resistance question, because a clinical isolate rarely carries only one mechanism. Screening the Gram-positive panel rather than MRSA alone shows whether the same call holds across E. faecium, S. pneumoniae and the rest.